Beam Therapeutics Inc. completed the transfer of certain assets and rights to Eli Lilly and Company, including opt-in rights to co-develop and co-commercialize base editing programs for cardiovascular disease. Beam received a $200 million upfront payment and may receive up to $350 million in future payments. Additionally, Beam sold 2,004,811 shares of common stock to Lilly for $50 million.